Designer Cytokine Hyper Interleukin 11 (H11) is a Megakaryopoietic Factor

Overview

Journal Int J Med Sci

Specialty General Medicine

Date 2013 Jul 23

PMID 23869192

Citations 5

Authors

Hanna Dams-Kozlowska

Eliza Kwiatkowska-Borowczyk

Katarzyna Gryska

Andrzej Mackiewicz

Affiliations

Soon will be listed here.

Abstract

Interleukin-11 (IL-11) displays megakaryopoietic activity. We constructed super-cytokine Hyper- IL11 (H11) by linking soluble IL-11 receptor α (sIL-11Rα) with IL-11, which directly targets β-receptor (gp130) signal transducing subunit. The effects of H11 on hematopoiesis with a focus on megakaryopoiesis were studied. The expansion, differentiation and type of colony formation of cord blood progenitor Lin-CD34+ cells were analyzed. H11 was more effective than recombinant human IL-11 (rhIL-11) in enhancement of the Lin-CD34+ cells expansion and differentiation into megakaryocytes (Mk). It induced higher expression of CD41a and CD61 antigens, resulting in a substantially larger population of CD34-CD41a(high)CD61(high) cells. H11 treatment led to increased number of small and mainly medium megakaryocyte colony formation (Mk-CFU). Moreover, it induced the formation of a small number of large colonies, which were not observed following rhIL-11 treatment. Significantly higher number of H11 derived Mk colonies released platelets-like particles (PLP). Furthermore, H11 was considerably more potent than rhIL-11 in promoting differentiation of Lin-CD43+ cells toward erythrocytes. Our results indicate that H11 is more effective than rhIL-11 in enhancing expansion of early progenitors and directing them to megakaryocyte and erythroid cells and in inducing maturation of Mk. Thus, H11 may prove beneficial for thrombocytopenia treatment and/or an ex vivo expansion of megakaryocytes.

Citing Articles

Application and investigation of thrombopoiesis-stimulating agents in the treatment of thrombocytopenia.

Huang L, Xu J, Zhang H, Wang M, Zhang Y, Lin Q Ther Adv Hematol. 2023; 14:20406207231152746.

PMID: 36865986 PMC: 9972067. DOI: 10.1177/20406207231152746.

IVIg increases interleukin-11 levels, which in turn contribute to increased platelets, VWF and FVIII in mice and humans.

Nguyen A, Repesse Y, Ebbo M, Allenbach Y, Benveniste O, Vallat J Clin Exp Immunol. 2021; 204(2):258-266.

PMID: 33512707 PMC: 8062997. DOI: 10.1111/cei.13580.

GM-CSF and IL-4 are not involved in IVIG-mediated amelioration of ITP in mice: a role for IL-11 cannot be ruled out.

Lewis B, Leontyev D, Neschadim A, Blacquiere M, Branch D Clin Exp Immunol. 2018; 193(3):293-301.

PMID: 29704458 PMC: 6150254. DOI: 10.1111/cei.13144.

The Potential Role of Senescence As a Modulator of Platelets and Tumorigenesis.

Valenzuela C, Quintanilla R, Moore-Carrasco R, Brown N Front Oncol. 2017; 7:188.

PMID: 28894697 PMC: 5581331. DOI: 10.3389/fonc.2017.00188.

Effects of Designer Hyper-Interleukin 11 (H11) on Hematopoiesis in Myelosuppressed Mice.

Dams-Kozlowska H, Kwiatkowska-Borowczyk E, Gryska K, Lewandowska A, Marszalek A, Adamczyk S PLoS One. 2016; 11(5):e0154520.

PMID: 27144685 PMC: 4856347. DOI: 10.1371/journal.pone.0154520.

References

Quesniaux V, Clark S, Turner K, FAGG B . Interleukin-11 stimulates multiple phases of erythropoiesis in vitro. Blood. 1992; 80(5):1218-23. View

Koike K, Nakahata T, Kubo T, Kikuchi T, Takagi M, Ishiguro A . Interleukin-6 enhances murine megakaryocytopoiesis in serum-free culture. Blood. 1990; 75(12):2286-91. View

Peeters K, Stassen J, Collen D, Van Geet C, Freson K . Emerging treatments for thrombocytopenia: increasing platelet production. Drug Discov Today. 2008; 13(17-18):798-806. DOI: 10.1016/j.drudis.2008.06.002. View

Reems J, Pineault N, Sun S . In vitro megakaryocyte production and platelet biogenesis: state of the art. Transfus Med Rev. 2009; 24(1):33-43. PMC: 2790431. DOI: 10.1016/j.tmrv.2009.09.003. View

Weich N, Wang A, Fitzgerald M, Neben T, Donaldson D, Giannotti J . Recombinant human interleukin-11 directly promotes megakaryocytopoiesis in vitro. Blood. 1997; 90(10):3893-902. View

Bunting S, Widmer R, Lipari T, RANGELL L, Steinmetz H, Moore M . Normal platelets and megakaryocytes are produced in vivo in the absence of thrombopoietin. Blood. 1997; 90(9):3423-9. View

Schwertschlag U, Trepicchio W, Dykstra K, Keith J, Turner K, Dorner A . Hematopoietic, immunomodulatory and epithelial effects of interleukin-11. Leukemia. 1999; 13(9):1307-15. DOI: 10.1038/sj.leu.2401514. View

Teramura M, Kobayashi S, Hoshino S, Oshimi K, Mizoguchi H . Interleukin-11 enhances human megakaryocytopoiesis in vitro. Blood. 1992; 79(2):327-31. View

Matsumura-Takeda K, Sogo S, Isakari Y, Harada Y, Nishioka K, Kawakami T . CD41+/CD45+ cells without acetylcholinesterase activity are immature and a major megakaryocytic population in murine bone marrow. Stem Cells. 2007; 25(4):862-70. DOI: 10.1634/stemcells.2006-0363. View

10.

Neben S, Donaldson D, Sieff C, Mauch P, Bodine D, Ferrara J . Synergistic effects of interleukin-11 with other growth factors on the expansion of murine hematopoietic progenitors and maintenance of stem cells in liquid culture. Exp Hematol. 1994; 22(4):353-9. View

11.

Gurney A, de Sauvage F, Moore M . Thrombocytopenia in c-mpl-deficient mice. Science. 1994; 265(5177):1445-7. DOI: 10.1126/science.8073287. View

12.

BURSTEIN S, Mei R, Henthorn J, Friese P, Turner K . Leukemia inhibitory factor and interleukin-11 promote maturation of murine and human megakaryocytes in vitro. J Cell Physiol. 1992; 153(2):305-12. DOI: 10.1002/jcp.1041530210. View

13.

Ciurea S, Hoffman R . Cytokines for the treatment of thrombocytopenia. Semin Hematol. 2007; 44(3):166-82. DOI: 10.1053/j.seminhematol.2007.04.005. View

14.

Kobayashi M, Laver J, Kato T, Miyazaki H, Ogawa M . Thrombopoietin supports proliferation of human primitive hematopoietic cells in synergy with steel factor and/or interleukin-3. Blood. 1996; 88(2):429-36. View

15.

de Sauvage F, Luoh S, Ryan A, Dowd M, Eaton D, Moore M . Physiological regulation of early and late stages of megakaryocytopoiesis by thrombopoietin. J Exp Med. 1996; 183(2):651-6. PMC: 2192470. DOI: 10.1084/jem.183.2.651. View

16.

Vadhan-Raj S . Management of chemotherapy-induced thrombocytopenia: current status of thrombopoietic agents. Semin Hematol. 2009; 46(1 Suppl 2):S26-32. DOI: 10.1053/j.seminhematol.2008.12.007. View

17.

Proulx C, Boyer L, Hurnanen D, Lemieux R . Preferential ex vivo expansion of megakaryocytes from human cord blood CD34+-enriched cells in the presence of thrombopoietin and limiting amounts of stem cell factor and Flt-3 ligand. J Hematother Stem Cell Res. 2003; 12(2):179-88. DOI: 10.1089/152581603321628322. View

18.

Weich N, Fitzgerald M, Wang A, Calvetti J, Neben S, Turner K . Recombinant human interleukin-11 synergizes with steel factor and interleukin-3 to promote directly the early stages of murine megakaryocyte development in vitro. Blood. 2000; 95(2):503-9. View

19.

Du X, Williams D . Interleukin-11: review of molecular, cell biology, and clinical use. Blood. 1997; 89(11):3897-908. View

20.

Kuter D, Begley C . Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. Blood. 2002; 100(10):3457-69. DOI: 10.1182/blood.V100.10.3457. View